Kintor Pharmaceutical has noted the announcement made yesterday by Beiersdorf AG regarding the innovation achievements of THIAMIDOL®630 and fair competition. The statement specifically mentioned Suzhou Kintor Pharmaceuticals and our core product KT-939. We hereby issues the following statement:
Since theestablishment, Kintor Pharmaceutical has always been a science-driven and rigorously innovative company. KT-939 is a proprietary cosmetic ingredient independently developed by our company, and protected by intellectual property rights. Its experimental data were published last year in a top international cosmetics journal, including comparative results with earlier products of the same mechanism (including THIAMIDOL®630).
As a novel cosmetic ingredient entering both domestic and international markets, KT-939 anticipates an open, fair, and healthy market environment. While we respect the intellectual property and commercial value of pioneers, we firmly oppose any bullying or opportunistic commercial practices.
We will continue to provide our global partners and consumers with compliant, safe, and effective KT-939 ingredients, and assume full legal responsibility for our products. We will also take all necessary legal and compliance measures to protect our clients’ rights and maintain a sound market order.
Finally, in cases where the Beiersdorf Group’s statement references Kintor Pharmaceutical and KT-939 without providing substantive evidence, resulting in reputational damage to our company and products or stock price fluctuations, we will continue to gather evidence and reserve the right to pursue legal action to safeguard the interests of our company and shareholders.
Kintor Pharmaceutical Ltd.March 19, 2026
精彩评论